Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Abstract Background Esophagogastric adenocarcinoma (EGA) currently represents a main cause of cancer related death. Despite an intensified treatment for locally advanced or metastatic EGA with a doublet chemotherapy consisting of a platinum compound and a fluoropyrimidine in combination with trastuz...
Main Authors: | Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer, Alexander Stein |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-06958-3 |
Similar Items
-
Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure
by: Shyam Aggarwal
Published: (2015-11-01) -
Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
by: Liu M, et al.
Published: (2018-01-01) -
Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
by: Wai Cheong Soon, et al.
Published: (2014-09-01) -
Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats
by: Juste Maneikyte, et al.
Published: (2020-08-01) -
Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
by: Xiaoying Hou, et al.
Published: (2021-09-01)